3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
6
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Breast
1
Conditions
Colorectal Neoplasms
2
Interventions
Oxaliplatin
1004
Fluorouracil
800
Capecitabine
764
Gemcitabine
650
Leucovorin
559
Irinotecan
537
Bevacizumab
513
Radiotherapy
460
Cisplatin
440
Drug Therapy
298
Cetuximab
280
Surgical Procedures, Operative
229
Paclitaxel
228
S 1 (combination)
217
pembrolizumab
205
Docetaxel
199
130-nm albumin-bound paclitaxel
196
Nivolumab
193
sintilimab
191
Radiosurgery
190
lenvatinib
180
Folfox protocol
179
Sorafenib
178
Albumin-Bound Paclitaxel
173
apatinib
170
tislelizumab
161
camrelizumab
160
Neoadjuvant Therapy
158
Blood Specimen Collection
154
durvalumab
148
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
mirdametinib
×
Gastrointestinal
×
Clear all
NCT02039336
2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2
Completed
35 enrolled
NCT02510001
2021-07-13
MErCuRIC1
University of Oxford
Phase 1
Completed
82 enrolled
36 charts